Macular Disease Foundation Australia has responded to the Independent Review of the NDIS Act.
Read MoreMacular Disease Foundation Australia has responded to the Independent Review of the NDIS Act.
Read MoreFrom 1 October 2015, the PBS listing for Eylea® includes the treatment of macula oedema from either diabetic retinopathy or central retinal vein occlusion.
Read MoreMDFA says the addition of ranibizumab (Lucentis) to the Pharmaceutical Benefits Scheme provides patients with affordable access to treatment for diabetic macular oedema and retinal vein occlusion.
Read MoreMDFA has voiced its concern regarding the economic impact of diabetic macular oedema (DMO) in Australia.
Read MoreWe’ve audited the six largest health funds to find out the benefits they offer for low vision aids and technology.
Read MoreAfter extensive lobbying by MDFA, SA Health has confirmed funding for an additional seven eye clinics per month.
Read MoreMDFA has been advocating for our community on the issue of PIN-only authorisation credit cards.
Read MoreMDFA has welcomed new treatment options for diabetic macular oedema and retinal vein occlusion.
Read MoreWe have represented the interests of those with vision loss to major financial institutions and card schemes on PIN-only authorisation.
Read More